Evidence map›Paper›PMID 17333210›Full record

ArticlePediatric surgery international2007

Glicentin inhibits internalization of enteric bacteria by cultured INT-407 enterocytes.

Masahiro Chiba, Yutaka Sanada, Shinya Kawano, Masayuki Murofushi, Ichiro Okada, Yasuo Yoshizawa, Akira Gomi, Masashi Yatsuzuka, Akira Toki, Yoshinori Hirai

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Pediatric surgery international, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Masahiro ChibaPediatric Surgery Services, Showa University School of Medicine, Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, 227-8501, Japan. CYH02471@nifty.com
Yutaka Sanada
Shinya Kawano
Masayuki Murofushi
Ichiro Okada
Yasuo Yoshizawa
Akira Gomi
Masashi Yatsuzuka
Akira Toki
Yoshinori Hirai
Showa University Fujigaoka Hospital · JPShowa University · JPShowa University Northern Yokohama Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glicentin, the main component of enteroglucagon, has trophic effects on intestinal mucosa. It may also have an inhibitory effect on extraintestinal invasion of enteric bacteria. We have established an in vitro bioassay system for determining the effects of recombinant human glicentin on bacterial internalization by confluent enterocytes. An INT-407 cell line was serum-deprived for 2 days and was then treated on transwell filters for 24 h with a medium containing one of the following: glicentin 100 ng-1 microg/ml, glucagons-like peptide-2 (GLP-2) 1 microg/ml, 10% fetal bovine serum (FCS), or without any growth factors. Pure cultures of Salmonella enteritidis, Escherichia coli, and Enterococcus faecalis were introduced to the upper chambers of the filter units. Following 2 h of incubation the numbers of bacteria in the lower chambers were measured. Pretreatment of enterocytes with glicentin inhibited bacterial internalization compared to untreated or GLP-2 enterocytes. Glicentin was associated with inhibition of enterocyte internalization of enteric bacteria by a mechanism that might be related to the integrity of the enterocyte adhesive junctions and tight junctions and to the production of sIgA. Glicentin seems to have a function as a barrier-sustaining agent that inhibits extraintestinal invasion of enteric bacteria.

Indexed as

Bacterial TranslocationCell LineCell SurvivalDose-Response Relationship, DrugEnterococcus faecalisEnterocytesEscherichia coliGlicentinGlucagon-Like Peptide 2HumansPeptide FragmentsRecombinant ProteinsSalmonella enteritidisGlicentinGlucagon-Like Peptide 2glucagon-like peptide-2 (3-33)Peptide FragmentsRecombinant Proteins

Identifiers

PMID17333210
OpenAlexW2015422740

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.